Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation safe gene-editing therapies
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Berkeley, CA, USA
Acrigen Biosciences develops novel high precision gene-editing systems. The company seeks to identify and develop next-generation CRISPR-Cas nucleases using its proprietary AcrTAIN™ bioinformatics discovery software platform. The company also develops its proprietary ErAcr proteins - Engineered Recombinant Anti-CRISPR proteins - that selectively inhibit off-target editing. The company raised seed funding in September 2021.